Tovecimig (CTX-009)

Second-line advanced biliary tract cancer

Also known as ABL001

Manufacturer: Compass Therapeutics
Regulatory submission: BLA planned for the fourth quarter of 2026
Launch: Anticipated in 2027
Last updated: September 21, 2026

Section

Product information and disease description Product description

Product information

65 evidence topics · 20 sources

Generic, brand name and therapeutic class of product5 evidence topics · 6 sources
Dosage forms and strengths2 evidence topics · 3 sources
Average sales price and wholesale acquisition cost3 evidence topics · 4 sources
American hospital formulary service (AHFS), or other drug classification1 evidence topic · 2 sources
Indication5 evidence topics · 7 sources
Pharmacology12 evidence topics · 5 sources
Contraindications/Warnings/Precautions/Adverse effects7 evidence topics · 7 sources
Special populations4 evidence topics · 4 sources
Drug/Drug, drug/disease interactions3 evidence topics · 3 sources
Dosing and administration7 evidence topics · 5 sources
Access and distribution3 evidence topics · 4 sources
Co-prescribed/Concomitant therapies5 evidence topics · 3 sources
Product comparison8 evidence topics · 8 sources

Effect of Tovecimig on quality measures

Product-specific effect on quality measures

No evidence found.